HIF-1α inhibition promotes the efficacy of immune checkpoint blockade in the treatment of non-small cell lung cancer - Luo, Fan; Lu, Fei-Teng; Cao, Jia-Xin; Ma, Wen-Juan; Xia, Zeng-Fei; Zhan, Jian-Hua; Zeng, Kang-Mei; Huang, Yan; Zhao, Hong-Yun; Zhang, Li (Cancer letters, 2022)
Keywords: Animal models; Animals; Apoptosis; Blood; Cancer therapies; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - pathology; CD8 antigen; Cell culture; EMT; Gene expression; Granzyme B; HIF-1α; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit - genetics; Hypoxia-inducible factor 1a; Immune Checkpoint Inhibitors; Immunohistochemistry; Immunosuppression; Immunotherapy; Laboratories; Ligands; LOXL2; Lung cancer; Lung Neoplasms - genetics; Lymphocytes; Lymphocytes T; Lymphocytes, Tumor-Infiltrating - metabolism; Medical prognosis; Metastasis; Mice; Non-small cell lung carcinoma; NSCLC; Patients; PD-1 protein; Phenotypes; Prognosis; Proteins; Signal transduction; Small cell lung carcinoma; Synergism; Tumors; Beijing China; United States--US; China; HIF-1α; Prognosis; NSCLC; EMT; Immunotherapy; LOXL2